Prostate
NxThera closes $18M Series C, wins CE Mark for Rezum prostate device
NxThera said it closed on a Series C round worth $18.2 million and won CE Mark approval for its Rezum treatment for benign prostatic hyperplasia.
Maple Grove, Minn.-based NxThera’s device uses steam to reduce the size of the prostate to relieve urinary symptoms from BPH, according to NxThera’s website.
GPOs: Premier inks new supply contracts
Group purchasing organization Premier Healthcare Alliance inked a pair of new contracts with U.S. medical device companies.
Deals for oral care products went to Kimberly-Clark (NYSE:KMB) and to hospital supplies company Sage Products.
Prostate cancer: AngioDynamics wins FDA nod for NanoKnife trial
AngioDynamics (NSDQ:ANGO) won a green light from the FDA for a clinical trial of its NanoKnife device for treating prostate cancer.
Profound Medical launches clinical trial for prostate cancer ablation treatment
Profound Medical said it launched a study of its transurethral ultrasound ablation device for treating prostate cancer
The 30-patient trial will examine whether the device, which treats the entire prostate gland in 1 session using MRI-guided ultrasound energy, can improve patients quality of life.
The pros and cons of prostate cancer screening | MassDevice.com On Call
MASSDEVICE ON CALL — The debate over prostate cancer screening took a rather conservative step forward this month with the American College of Physicians recommending that doctors only provide screenings to well-informed patients who’ve opted for a prostate-specific antigen, or PSA, test.
The battle over robotic surgery keeps heating up
Physician bias in prostate cancer treatment? | MassDevice.com On Call
MASSDEVICE ON CALL — A Mayo Clinic study of prostate cancer treatment found that active surveillance for low-risk patients was prescribed in frequently, and that physicians tend to lean toward their own fields when recommending more aggressive treatment.
"While active surveillance is widely regarded as an effective strategy for managing low-risk prostate cancer, a Mayo Clinic study of 643 urologists and radiation oncologists found that only 21% of physicians studied recommended the strategy while 47% recommended surgery and 32% recommended radiation therapy," according to a press release.
Battle in Silicon Valley: Device makers trade barbs in the fight to gain share in robot assisted procedures
Study: Robot assisted prostate surgery may lower rates of incontinence, impotence
Robot assisted prostate surgery may lower rates of urinary incontinence and post-surgery impotence when compared with minimally invasive laparoscopy, according to a small Italian study.
The study only comprised 120 patients who were randomized to receive a prostatectomy with either an unnamed robot assistant or with tiny tools manipulated by hand. All surgeries were performed by a single surgeon.
MassDevice.com +3 | The top 3 med-tech stories for July 24, 2012
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with MassDevice +3.